Bi-Specific mAbs Market Expands with Advances in Immuno-Oncology and Targeted Therapies | Amgen, Inc., Bayer AG, Dow Pharmaceutical Solutions, ImmunGene, Inc.

The global Bi-Specific MAbS Market size was valued USD 12.34 billion in 2024, and is estimated to reach USD 479.18 billion by 2033, growing at a CAGR of 43.7% during the forecast period (2025-2033).

Bi-Specific Monoclonal Antibodies Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With growing adoption in oncology, autoimmune disorders, and infectious disease treatments, the report delivers strategic insights for stakeholders in biologics and next-generation antibody therapeutics from 2025 to 2033.

In 2025, innovative preclinical candidates including bispecific, trispecific antibodies, and bispecific ADCs were unveiled by Innovent Biologics at the AACR Annual Meeting, reflecting strong oncology-driven pipeline momentum. Globally, the bi-specific antibody field continues to scale rapidly by early 2025, 19 bispecific antibodies were approved worldwide, generating over US $12 billion in annual sales.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/bi-specific-mabs-market?ophp

Bi-specific mAbs are engineered antibodies capable of binding to two different antigens simultaneously, enabling targeted therapeutic effects in cancer, autoimmune, and infectious diseases. The market is growing due to promising clinical trial outcomes, rising oncology drug approvals, and increased biopharma investment in next-generation biologics.

Bi-Specific MAbS Market Competitors Overview:

Amgen, Inc., Bayer AG, Dow Pharmaceutical Solutions, ImmunGene, Inc., Immunocore Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, Hengrui Medicine, SYSVAX and Hisun Pharmaceutical

Important Industry Updates of 2023, 2024 and 2025:

February 2025 - Regeneron Pharmaceuticals expanded its oncology pipeline through a $500 million collaboration with CytomX Therapeutics, leveraging Probody® technology to develop novel bispecific antibodies with enhanced tumor selectivity.

May 2025 - Roche entered a $1.2 billion licensing and co-development agreement with Zymeworks for a next-generation bispecific HER2-targeting candidate, strengthening its solid tumor therapeutic portfolio.

July 2025 - Amgen acquired Teneobio's bispecific platform assets for undisclosed terms, aiming to broaden its multispecific antibody development capabilities across oncology and autoimmune indications.

Methodology and Scope

The Bi-Specific MAbS Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/bi-specific-mabs-market?ophp

Bi-Specific MAbS Market Segments Overview:

By Type (Catumaxomab, Blinatumomab, Duligotumab, Others), By End User ( Research Institutes, Hospitals, Others)

Regional Overview for Bi-Specific MAbS Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=bi-specific-mabs-market?ophp

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the Bi-Specific MAbS market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the Bi-Specific MAbS market?

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription?ophp

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.